Tissue Engineering Market Share

Global Tissue Engineering Market Overview

The Tissue Engineering Market Size was valued at USD 1.2 billion in 2022 and is projected to grow from USD 1.4 Billion in 2023 to USD 3.3 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13% during the forecast period (2023 - 2032). Major market drivers for the expansion include the rising prevalence of chronic diseases and trauma situations, as well as increased knowledge of tissue engineering, 3D bio-printing technology, and future pipeline goods.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

According to the leading player in the industry of 3D printing, 3D Systems, in May 2021, they bought Germany’s Additive Works GmbH to boost their simulation abilities and speedily optimize their large-scale 3-D printing processes.

Organogenesis Inc.’s product lines – Affinity, PuraPly AM, NuShield, Apligraf, Novachor and Organogenesis Physician Solutions – will take over the upcoming Symposium on Advanced Wound Care (SAWC) Spring Conference which is planned for April 6-10th2019 in Phoenix.

When Yibing Qyang secured a grant worth $2 million from NIH in March 2024, Associate Professor of Medicine (Cardiology) and of Pathology at Yale Research. The purpose of giving out this R01 grant was to create an artificial blood vessel by using pluripotent stem cells and tissue engineering. Notably, this is intended not only as a proof-of-concept study but also as the first step toward generating mechanically active tubules for the clinical treatment of patients with single ventricle congenital heart disease.

Recently, Texas A&M University scientists developed an electronic skin (E-skin), which has been engineered through nanotechnology-based hydrogels for sensing temperature and electronically adjustability similar to human skin cells.

A collaboration between RegenLab and Long Island University Brooklyn was established in June 2023, and it aimed to create a cell therapy and tissue engineering-specific industrial innovation accelerator.

AlloMend® Duo was the principal target of AlloSource in May 2023. It is a product for tissue regeneration and helps repair or replace soft tissue defects over an extended period.

In January 2023, Zimmer Biomet announced its intention to buy Embody Inc., a US-based company that specializes in developing collagen implants for healing soft tissues.

By September 2022, Columbia University scientists had grown functional human lungs from stem cells. By mixing three-dimensional (3D) bioprinting and tissue engineering techniques, they formed a structure resembling a lung that could be used as transplant material later on.

University of Illinois scientists have developed a new bioink for the creation of functional human organs since June 2022 using three-dimensional (3D) printing technology. Its bioink is made up of hydrogel consisting of live cell extracellular matrix (ECM) mimic – this provides favorable conditions to support cell growth.

Tissue Engineering Market Trends

• 
  

  Rising cases of road accidents to propel market growth

  
  

The expansion in the creation of tissue engineering solutions is shown to be influenced by the increase in chronic diseases, traffic accidents, and trauma injuries. Due to an increase in the prevalence of chronic diseases, trauma cases, and an extended average life duration, more people are in need of bone implants. 

Since they seriously injure bones and organs, road accidents rank among the leading causes of death in the globe. According to the WHO, traffic accidents cause 20 to 50 million injuries annually. Tissue engineering provides options for repairing injured tissues in place of surgery, organ transplantation, and mechanical device teaching. The growing prevalence of diabetes, obesity, and other disorders brought on by lifestyle changes, an aging population, and an increase in trauma cases are the primary factors driving the market of tissue engineering. Thus, this factor is driving the market CAGR.

However, the growing demand for better therapeutic procedures for the restoration of damaged tissues or organs and the development of 3D bioprinting technology are the main factors driving the worldwide market of tissue engineering. Today, tissue engineering technology is widely used in clinical operations, and the majority of patients have received care using tissue engineering techniques. 14.4 million USD were invested globally in tissue engineering during the first quarter of 2019. Healthcare experts are increasingly turning to various therapeutic alternatives like organ transplantation or surgical repair in tissue engineering to address the significant and frequent medical problems of tissue and organ failure.

Furthermore, human cells, tissues (HCT/Ps), and cellular and tissue-based transplantation products like CARVYKTI (ciltacabtagene autoleucel), ABECMA (idecabtagene vicleucel), HEMACORD (HPC, cord blood), ALLOCORD (HPC, Cord Blood), LUXTURNA, and several other products have received approval from a number of federal health and human services, including the European Medical Agency (EMA) and the United States These products, including hematopoietic, ocular tissues, ligaments, and cartilage, among others, are widely used for medical treatments. 

Hospitals and biomedical research facilities are utilizing tissue engineering goods more frequently for transplants and other medical procedures, which is fueling the market's expansion in terms of revenue. In addition, top scientific research organisations use adult or embryonic stem cells for their own internal drug development software. Almost 2 million tissue transplants are given out year in the United States, but only about 1 million of those grafts are ever implanted, according to the Centers for Disease Control and Prevention (CDC). Thus, it is anticipated that this aspect will accelerate tissue engineering market revenue globally.

Tissue Engineering Market Segment Insights

Tissue Engineering Material Insights

The market segments of tissue engineering, based on material, includes Nano-fibrous Material, Biomimetic Material, Composite Material and Nano-composite Material. The biomimetic material segment held the majority share in 2022 in the Tissue Engineering Market data. Due to their capacity to mirror the characteristics of natural tissues and offer a setting that fosters cell development and tissue creation, biomimetic materials have demonstrated considerable promise in tissue engineering. By offering materials that may closely imitate the characteristics of natural tissues and facilitate the production of useful, healthy tissues, biomimetic materials have the potential to revolutionize tissue engineering.

Figure 2: Tissue Engineering Market, by Material, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Tissue Engineering Application Insights

The Tissue Engineering Market segmentation, based on application, includes Orthopedics, Musculoskeletal and Spine, Skin/Integumentary, Cancer, Dental, Cardiology, Urology, Neurology, Cord Blood & Cell Banking and GI & Gynecology. The musculoskeletal spine segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030 due to increased use of tissue-engineered products for orthopedic and musculoskeletal applications, increased commercialization of products for bone and cartilage repair, widespread product availability, and an increase in musculoskeletal disorders as a result of increased public awareness of these products.

Tissue Engineering Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America tissue engineering market accounted for USD 0.6 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period because the number of elderly people is growing and stem cell therapy is becoming more well known. Additionally, a bigger percentage of the local market is encouraged by the availability of private and public funding, significant healthcare spending, and sophisticated technologies for the detection and treatment of chronic illnesses.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: Tissue Engineering Market Share by Region 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Asia Pacific tissue engineering market accounts for the second-largest market share. One of the nations leading the way in tissue engineering science advancement is Japan. It is also anticipated that the prevalence of clinical illnesses like cancer would rise, which will promote expansion in the Asian market of tissue engineering. The development of the sector is also being fueled by factors like regional medical tourism and the development of 3D bioprinting. Moreover, China market of tissue engineering held the largest market share, and the India market of tissue engineering was the fastest growing market in the region.

Europe tissue engineering Market is expected to grow at the fastest CAGR from 2022 to 2030 due to the rising demand for advanced healthcare services in emerging economies, the region's increasing R&D sector, and the increased presence of important companies in the market. Furthermore, the industry has developed quickly due to expanding healthcare infrastructure and an emphasis on regenerative medicine. Further, the UK market of tissue engineering held the largest market share, and the Germany market of tissue engineering was the fastest growing market in the region.

Tissue Engineering Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of tissue engineering grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the tissue engineering industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the global tissue engineering industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, tissue engineering industry has provided medicine with some of the most significant benefits. The tissue engineering market major player such as Stryker, Allergan, Medtronic, Zimmer, Baxter International, Integra LifeSciences, Organovo Holdings Inc, Cook Medical, DePuy Synthes and Acelity.

A publicly traded manufacturer of medical equipment is Zimmer Biomet. To make aluminium splints, it was established in 1927. The company has its headquarters in Warsaw, Indiana, and is a part of the medical devices industry cluster there. In July 2022, the Hospital for Special Surgery (HSS) and Zimmer Biomet (ZB) Innovation Center for Artificial Intelligence (AI) in Robotic Joint Replacement is a joint venture between Zimmer Biomet, a U.S.-based corporation, and HSS. Under this agreement, doctors will receive recommendations based on data for robotic-assisted joint surgery.

A leading manufacturer of medical devices with its headquarters in Princeton, New Jersey, is Integra LifeSciences. The company was established in 1989 and makes products for general, reconstructive, and neurosurgical procedures. The first commercially reproducible skin tissue, Integra artificial skin, was used to heal serious burns and other skin wounds. In July 2021, positive clinical outcomes using PriMatrix Dermal Repair Scaffold to treat difficult-to-heal diabetic foot ulcers were reported by Integra LifeSciences Holding Corporation (DFUs).

Key Companies in the market of tissue engineering includes

• Stryker


• Allergan


• Medtronic


• Zimmer


• Baxter International


• Integra LifeSciences


• Organovo Holdings Inc


• Cook Medical


• DePuy Synthes


• Acelity

Tissue Engineering Industry Developments

May 2022: Quali-Pure HGP 2000, a novel endotoxin-controlled pharmaceutical-grade gelatin especially created for vaccinations and wound healing applications, has been introduced by Rousselot, the health brand of Darling Ingredients.

October 2021: A contract was reached between EyeProGPO, LLC, a healthcare organisation, and BioTissue, a U.S.-based innovator in tissue engineering and regenerative medicine, to provide purchase volume discounts for biologic ocular transplantation graft goods and regenerative healing solutions.

Tissue Engineering Market Segmentation

Tissue Engineering Material Outlook (USD Billion, 2019-2032)

• Nano-fibrous Material


• Biomimetic Material


• Composite Material


• Nano-composite Material

Tissue Engineering Application Outlook (USD Billion, 2019-2032)

• Orthopedics


• Musculoskeletal and Spine


• Skin/Integumentary


• Cancer


• Dental


• Cardiology


• Urology


• Neurology


• Cord Blood & Cell Banking


• GI & Gynecology

Tissue Engineering Regional Outlook (USD Billion, 2019-2032)

• 
  

  North America

  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  

  Europe

  
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  

  Asia-Pacific

  
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America